Skip Navigation

Cardiovascular Research 2002 53(4):862-868; doi:10.1016/S0008-6363(01)00544-2
© 2002 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Camilión de Hurtado, M. C.
Right arrow Articles by Cingolani, H. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camilión de Hurtado, M. C.
Right arrow Articles by Cingolani, H. E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2002, European Society of Cardiology

Regression of cardiomyocyte hypertrophy in SHR following chronic inhibition of the Na+/H+ exchanger

María C. Camilión de Hurtado1, Enrique L. Portiansky1, Néstor G. Pérez1, Oscar R. Rebolledo and Horacio E. Cingolani*,1

Centro de Investigaciones Cardiovasculares, Facultad de Ciencias Médicas, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata, 60 y 120 (1900) La Plata, Argentina

* Corresponding author. Tel.: +54-221-483-4833; fax: +54-221-425-5861 cicme{at}infovia.com.ar

Objective: Experiments were performed to examine the effect of chronic inhibition of the Na+/H+ exchanger isoform-1 (NHE-1) on cardiac hypertrophy of spontaneously hypertensive rats (SHR). Methods: SHR were orally treated during 1 month with two different doses (0.3 and 3.0 mg/kg/day) of the NHE-1 inhibitor, cariporide, or nifedipine (10.0 mg/kg/day). Results: The two doses of cariporide did not differ in their effects after 1 month of treatment, since both induced a slight decrease in systolic blood pressure (SBP) of ~6 mmHg and regression of the heart weight to body weight ratio (mg/g) from 3.28±0.05 to 3.04±0.05 (0.3 mg) and 2.99±0.10 (3.0 mg, P<0.05). Nifedipine, given for the same period, produced similar reduction in the hypertrophy index (3.03±0.05), but with a much greater decrease in arterial pressure (35.6±7.4 mmHg). Chronic treatment with cariporide induced a complete regression of the augmented cross sectional area of left ventricular myocytes without significant changes in collagen content, serum procollagen 1 propeptide levels or myocardial distensibility. Conclusions: NHE inhibition represents a novel approach to induce regression of pathological hypertrophy of the heart. The finding can be rationalized mechanistically by previous in vitro studies suggesting a role of the NHE in the development of myocardial hypertrophy.

KEYWORDS Fibrosis; Hypertension; Hypertrophy; Ion exchangers; Na/H exchanger


1 Established Investigators of Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
C. D. Garciarena, C. I. Caldiz, E. L. Portiansky, G. E. Chiappe de Cingolani, and I. L. Ennis
Chronic NHE-1 blockade induces an antiapoptotic effect in the hypertrophied heart
J Appl Physiol, April 1, 2009; 106(4): 1325 - 1331.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Darmellah, C. Rucker-Martin, and D. Feuvray
ERM proteins mediate the effects of Na+/H+ exchanger (NHE1) activation in cardiac myocytes
Cardiovasc Res, February 1, 2009; 81(2): 294 - 300.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.